Clinical significance of platelet‑derived growth factor receptor‑β gene expression in stage II/III gastric cancer with S‑1 adjuvant chemotherapy

  • Authors:
    • Akio Higuchi
    • Takashi Oshima
    • Kazue Yoshihara
    • Kentaro Sakamaki
    • Toru Aoyama
    • Nobuyasu Suganuma
    • Naoto Yamamoto
    • Tsutomu Sato
    • Haruhiko Cho
    • Manabu Shiozawa
    • Takaki Yoshikawa
    • Yasushi Rino
    • Chikara Kunisaki
    • Toshio Imada
    • Munetaka Masuda
  • View Affiliations

  • Published online on: December 14, 2016     https://doi.org/10.3892/ol.2016.5494
  • Pages: 905-911
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Overall survival remains unsatisfactory in stage II/III gastric cancer, even after curative surgery and adjuvant chemotherapy. Platelet‑derived growth factor receptor‑β (PDGFR‑β) is associated with the proliferation of cancer cells. The present study therefore investigated the association of PDGFR‑β gene expression with patient outcome in 134 stage II/III gastric cancer patients who received adjuvant chemotherapy with S‑1. Relative PDGFR‑β gene expression was measured in surgical cancer tissue and adjacent normal mucosa specimens by reverse transcription‑quantitative polymerase chain reaction. The PDGFR‑β gene expression levels were found to be significantly higher in the cancer tissues compared with the adjacent normal mucosa. A high level of PDGFR‑β gene expression was associated with a significantly poorer 5‑year overall survival rate compared with a low level of PDGFR‑β expression. Upon multivariate analysis, PDGFR‑β gene expression was found to be an independent predictor of survival. Overall, the study indicates that PDGFR‑β overexpression in gastric cancer tissues is a useful independent predictor of outcome in patients with stage II/III gastric cancer who receive adjuvant chemotherapy with S‑1.
View Figures
View References

Related Articles

Journal Cover

February-2017
Volume 13 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Higuchi A, Oshima T, Yoshihara K, Sakamaki K, Aoyama T, Suganuma N, Yamamoto N, Sato T, Cho H, Shiozawa M, Shiozawa M, et al: Clinical significance of platelet‑derived growth factor receptor‑β gene expression in stage II/III gastric cancer with S‑1 adjuvant chemotherapy. Oncol Lett 13: 905-911, 2017.
APA
Higuchi, A., Oshima, T., Yoshihara, K., Sakamaki, K., Aoyama, T., Suganuma, N. ... Masuda, M. (2017). Clinical significance of platelet‑derived growth factor receptor‑β gene expression in stage II/III gastric cancer with S‑1 adjuvant chemotherapy. Oncology Letters, 13, 905-911. https://doi.org/10.3892/ol.2016.5494
MLA
Higuchi, A., Oshima, T., Yoshihara, K., Sakamaki, K., Aoyama, T., Suganuma, N., Yamamoto, N., Sato, T., Cho, H., Shiozawa, M., Yoshikawa, T., Rino, Y., Kunisaki, C., Imada, T., Masuda, M."Clinical significance of platelet‑derived growth factor receptor‑β gene expression in stage II/III gastric cancer with S‑1 adjuvant chemotherapy". Oncology Letters 13.2 (2017): 905-911.
Chicago
Higuchi, A., Oshima, T., Yoshihara, K., Sakamaki, K., Aoyama, T., Suganuma, N., Yamamoto, N., Sato, T., Cho, H., Shiozawa, M., Yoshikawa, T., Rino, Y., Kunisaki, C., Imada, T., Masuda, M."Clinical significance of platelet‑derived growth factor receptor‑β gene expression in stage II/III gastric cancer with S‑1 adjuvant chemotherapy". Oncology Letters 13, no. 2 (2017): 905-911. https://doi.org/10.3892/ol.2016.5494